Protocol 20-348: A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR/Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma https://clinicaltrials.gov/ct2/show/NCT04891289

Protocol 23-203: Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer (A022004) (CIRB) https://clinicaltrials.gov/ct2/show/NCT05710406

Protocol 22-068: Identification and Treatment of Micrometastatic Disease in Stage III Colon Cancer https://clinicaltrials.gov/ct2/show/NCT03803553 

Protocol 22-168:  Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance https://clinicaltrials.gov/ct2/show/NCT05892068

Protocol 22-334: A Randomized, Phase II Study of Enzalutamide, Enzalutamide with Mifepristone, and Treatment of Physician’s Choice in Patients with AR+ Metastatic Triple-Negative or ER-Low Breast Cancer https://clinicaltrials.gov/ct2/show/NCT06099769

Protocol 21-018:  Phase II of Neoadjuvant Olaparib in Combination with Pembrolizumab in Patients with Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer and Germline Mutations in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT05203445

Protocol 22-074:  Phase 2 Randomized Control Trial of Evexomostat (SDX-7320) in Combination with Eribulin for Patients with Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study https://clinicaltrials.gov/ct2/show/NCT05570253 

Protocol 23-274:  A Phase Ib/II trial of Lenvatinib plus Pembrolizumab plus Fulvestrant in ER-positive/ HER2-negative Metastatic Breast Cancer https://clinicaltrials.gov/ct2/show/NCT06110793

Protocol 18-427: Phase 2 study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and TP53-Mutant Mantle Cell Lymphoma (MCL) https://clinicaltrials.gov/ct2/show/NCT03824483

Protocol 21-210:  A Phase II/III Randomized Study of R-miniCHOP with or without CC-486 (Oral Azacitidine) in Participants Aged 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (S1918) (CIRB) https://clinicaltrials.gov/ct2/show/NCT04799275

Protocol 23-319: Pilot Study of Glofitamab and Lenalidomide in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with a BTK Inhibitor https://clinicaltrials.gov/ct2/show/NCT06192888

Protocol 23-355: A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1) https://clinicaltrials.gov/ct2/show/NCT04663347

Protocol 23-261 An International, Phase 3, Randomized, Multicenter, Open Label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and, or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT) (WCG IRB) - ALL PROTOCOL ACTIVITIES ARE ALLOWED AT BSK https://clinicaltrials.gov/ct2/show/NCT03673501

Protocol 23-169 A Phase I Trial of CRD3874-SI, a STING Agonist, in Patients with Advanced/Metastatic Sarcoma and Merkel Cell Carcinoma (LIMITED PROTOCOL ACTIVITIES ALLOWED AT BSK) https://clinicaltrials.gov/ct2/show/NCT06021626

Protocol 21-520 Phase 3 Randomized Double-Blind Study of Abemaciclib versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma (LIMITED PROTOCOL ACTIVITIES ARE ALLOWED AT BSK) https://clinicaltrials.gov/ct2/show/NCT05886634

Protocol 23-353 A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies - LIMITED PROTOCOL ACTIVITIES ALLOWED AT BSK https://clinicaltrials.gov/ct2/show/NCT05130827

Protocol 23-092 A Phase 1b/2 Trial of Lurbinectedin plus Doxorubicin in Leiomyosarcoma (MAJORITY OF PROTOCOL ACTIVITIES ARE ALLOWED AT BSK) https://clinicaltrials.gov/ct2/show/NCT05099666

Protocol 22-342 A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies https://clinicaltrials.gov/ct2/show/NCT05006716 

Protocol 21-072 A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBodyTM-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome https://clinicaltrials.gov/ct2/show/NCT04623541

Protocol 23-073 Study M23-324: A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies https://clinicaltrials.gov/ct2/show/NCT05618028

Protocol 21-375 A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322) (WIRB) https://clinicaltrials.gov/ct2/show/NCT04965493

Protocol 18-427 Phase 2 study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL) https://clinicaltrials.gov/ct2/show/NCT03824483 

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects with Advanced/Metastatic Solid Tumors https://clinicaltrials.gov/ct2/show/NCT05150691 

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma (NRG-GY026) (CIRB) https://clinicaltrials.gov/ct2/show/NCT05256225 

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects with Advanced/Metastatic Solid Tumors https://clinicaltrials.gov/ct2/show/NCT05150691

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects with Advanced/Metastatic Solid Tumors

https://clinicaltrials.gov/ct2/show/NCT05150691

Protocol 21-475: Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC https://clinicaltrials.gov/ct2/show/NCT04819100

Protocol 21-152: Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based chemotherapy + Certolizumab in Patients with Resectable Stages II-III Lung Cancers https://clinicaltrials.gov/ct2/show/NCT04991025 

Protocol 21-132: A Phase 1 Open-Label Study of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) https://clinicaltrials.gov/ct2/show/NCT02803203

Protocol 22-180: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Protocol 20-405: Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, Pralsetinib, Atezolizumab, or GDC-6036 in Patients with Stages I-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, V600E, PD-L1 (>/= 1% tumor cells), or KRAS G12C Molecular Alterations (NAUTIKA) https://clinicaltrials.gov/ct2/show/NCT05048797 & https://clinicaltrials.gov/ct2/show/NCT01639508

Protocol 02-011: A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib https://clinicaltrials.gov/ct2/show/NCT04410796 

X20-086 Exempt protocol (PI: Dr. Daly, Study Contact – Kristina Stevanovic) MSK-IO@Home: Enhanced Telemedicine for Patients Initiating Single Agent Pembrolizumab

A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck https://clinicaltrials.gov/ct2/show/NCT05271604

A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) https://clinicaltrials.gov/ct2/show/NCT04675294 

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 as a Single Agent and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors https://clinicaltrials.gov/ct2/show/NCT04666688